QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=DE304EC9CDF11B7124964268841F1366;jsessionid=C57F5F3FC8F419FF7AD96B2ECA778D7B;jsessionid=5F6AE9A98A23FCF46B3723D281F6E0E8;jsessionid=28BC982DB5FE8AA63A340E7286C4C909;jsessionid=041F57258EB942CF23FA06DF14AA264B;jsessionid=AB4F1A77DF41C17E041E6D949CBC9B0B;jsessionid=919266CE10C059AB396532201B2334D4;jsessionid=A7030C9051C423561ED48BD96FC7A267 (gene)

1. Ataxin-2 sequesters Raptor into aggregates and impairs cellular mTORC1 signaling.
2. The polyglutamine protein ATXN2: from its molecular functions to its involvement in disease.
3. Clinical features, disease progression, and nuclear imaging in ATXN2-related parkinsonism in a longi…
4. ATXN2 is a target of N-terminal proteolysis.
5. A Case of Coexistent Spinocerebellar Ataxia Type 2 and Primary Progressive Multiple Sclerosis-Coinci…

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=DE304EC9CDF11B7124964268841F1366;jsessionid=C57F5F3FC8F419FF7AD96B2ECA778D7B;jsessionid=5F6AE9A98A23FCF46B3723D281F6E0E8;jsessionid=28BC982DB5FE8AA63A340E7286C4C909;jsessionid=041F57258EB942CF23FA06DF14AA264B;jsessionid=AB4F1A77DF41C17E041E6D949CBC9B0B;jsessionid=919266CE10C059AB396532201B2334D4;jsessionid=A7030C9051C423561ED48BD96FC7A267